MIAMI, Oct. 01, 2026 (GLOBE NEWSWIRE) — Watsco, Inc.’s (NYSE: WSO) Board of Directors has declared a regular quarterly cash dividend of $3.30 on each outstanding share of its Common and Class B common stock payable on October 30, 2026 to shareholders of record at the close of business on October 16, 2026.

Watsco has paid dividends to shareholders for 52 consecutive years. The Company’s philosophy is to share cash flow through dividends while keeping a conservative balance sheet with continued capacity to build its distribution network. Future changes in dividends will be considered in light of investment opportunities, cash flow, general economic conditions, and Watsco’s overall financial condition.

About Watsco

Watsco is the largest distributor in the highly fragmented North American HVAC market. Since entering distribution in 1989, Watsco has achieved an 18% compounded annual total shareholder return through a combination of organic growth and the acquisition of more than 70 market-leading businesses.

Watsco maintains a solid balance sheet, enabling sustained investments in growth, including the Company’s industry-leading technologies. Today, more than 70,000 contractors and technicians engage digitally, empowering them to adopt and integrate Watsco’s tools into their daily operations. The Company is also introducing AI-driven initiatives to leverage its extensive data assets and enrich the customer experience. The Company believes its technology ecosystem represents a durable and widening competitive advantage in its highly fragmented industry.

This document includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may address, among other things, our expected financial and operational results and the related assumptions underlying our expected results. These forward-looking statements are distinguished by use of words such as “will,” “would,” “anticipate,” “expect,” “believe,” “designed,” “plan,” or “intend,” the negative of these terms, and similar references to future periods. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from these expectations due to changes in economic, business, competitive market, new housing starts and completions, capital spending in commercial construction, consumer spending and debt levels, regulatory and other factors, including, without limitation, the effects of supplier concentration, competitive conditions within Watsco’s industry, the seasonal nature of sales of Watsco’s products, the ability of the Company to expand its business, insurance coverage risks and final GAAP adjustments. Detailed information about these factors and additional important factors can be found in the documents that Watsco files with the Securities and Exchange Commission, such as Form 10-K, Form 10-Q and Form 8-K. Forward-looking statements speak only as of the date the statements were made. Watsco assumes no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except as required by applicable law.

Barry S. Logan
Executive Vice President 
(305) 714-4102
e-mail: blogan@watsco.com

VUDD018 Completed as an Oblique Structural Test at Central–Makoba; Preliminary Logging Identifies Repeated Silica–Carbonate Alteration, Quartz–Carbonate Veining and Sulfides

VUDD019 Underway as the Company Advances Approximately 3,000-Meter 2026 Program

TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) — One Bullion Ltd. (“One Bullion” or the “Company”) (TSXV: OBUL), a gold exploration company holding complete ownership of three highly prospective exploration projects in Botswana, today announced the completion of diamond drill hole VUDD018 at its wholly owned Vumba Gold Project in northeastern Botswana. VUDD018 marks the completion of the second hole of the Company’s approximately 3,000-meter 2026 diamond drilling program, with drilling now underway on the third hole, VUDD019.

VUDD018 targeted the same Central–Makoba structure (VGT-01) as VUDD017, but was drilled as an oblique-angled hole, to cross the structure from a different direction. The goal was to test structural splays and intersections, vein stacking and possible controls on shoot geometry, while providing a second oriented-core view of the same system to build into the three-dimensional model.

Highlights

  • VUDD018 has been completed as the second hole of the 2026 program. The hole was designed as a 350-meter HQ drill hole, as an oblique structural test from 535,894 mE / 7,712,640 mN using 330° true / −60° planning geometry. Total depth of the hole was 350.85m.
  • These observations are preliminary visual descriptions and do not establish gold grade, mineralized widths or economic significance.
  • Preliminary lithological logging completed to date records an amphibolite-dominated sequence that is variably schistose, foliated and banded, with local carbonaceous, quartz-rich and garnetiferous intervals. Oxidized near-surface amphibolite passes into fresh rock at approximately 9.7 meters downhole.
  • Alteration logging completed to date records repeated intervals of silicification and carbonate alteration, locally with chlorite, across multiple intervals. Sulfide logging identified arsenopyrite with lesser pyrite in disseminated, banded and vein- or veinlet occurrences.
  • Quartz and quartz–carbonate veining is common in the logged portion of the hole, including irregular and folded vein sets and local brecciation.

The drill has been moved to VUDD019 and has commenced testing a deeper northern portion of Central–Makoba on the property. Drillhole was oriented at 267° true north and −69° dip, with a planned total depth of 425 meters. This hole is designed to test whether the deeper hydrothermal and structural corridor observed in VUDD017 continues northward and at depth.

“VUDD018 was deliberately drilled across the Target (VGT-01) from a different angle than VUDD017, and the preliminary logging is giving us an important second structural view of the system,” said Adam Berk, Chief Executive Officer of One Bullion. “With VUDD019 now underway as a deeper northern test, we are integrating the alteration, quartz–carbonate veining and sulfide styles observed in VUDD018 into our three-dimensional model, and laboratory assays remain essential to determining whether these visual hydrothermal features carry meaningful gold.”

No assay results for VUDD018 are available. The geological descriptions in this release are based on visual core logging and do not establish gold grade, mineralized widths, or economic mineralization. Logged interval lengths are downhole lengths and true widths are unknown.

VUDD018 — Central–Makoba Oblique Structural Hole

VUDD018 was designed to complement VUDD017 by crossing the Central–Makoba structural package obliquely. Logging is still underway, and the observations below therefore summarize the current state of the geological record rather than the final full-hole log.

Current Logged Depth / Interval Preliminary Observation
0.0–9.7 m Near-surface soil and oxidized/weathered amphibolitic rock, including fracture-controlled iron-oxide staining and local strong silicification.
9.7–276.5 m logged to date Predominantly fresh amphibolite, commonly schistose, foliated or banded, with local carbonaceous, quartz-rich and garnetiferous intervals.
Alteration logged to approximately 217 m Repeated silica and carbonate alteration, locally with chlorite; styles include pervasive, banded, vein-controlled and fracture-controlled alteration, with locally strong to very strong intensity.
Sulfides logged to 203 m Visually identified arsenopyrite is the dominant logged sulfide with lesser pyrite, occurring at multiple intervals in disseminated, banded and vein/veinlet-controlled styles.
Veining logged to 187 m Quartz, calcite and quartz–carbonate veins and veinlets are common. Local intervals show irregular or folded vein geometry and local brecciation.

The occurrence of sulfides, alteration and veining are not continuous across the intervals summarized above and should not be interpreted as a mineralized intercept. Their significance will be evaluated only after laboratory results, QA/QC review and geological/structural integration.

Sampling, Analysis and QA/QC
Core logging, photography, cutting and sampling are progressing at the Company’s secure core facility. The Company plans to sample the entire VUDD018 hole rather than only visibly altered or sulfide-bearing intervals. Half-core samples will be cut with a diamond saw at nominal one-meter intervals, adjusted to lithological, alteration and mineralogical contacts, with the remaining half-core retained for reference. Drill core will be sampled at nominal one-meter intervals, adjusted to geological contacts, with certified reference materials, blanks and duplicates included in the quality assurance and quality control (“QA/QC”) stream for submission to ALS Laboratories in South Africa.

Certified reference materials, blanks and duplicates will be inserted as part of the Company’s QA/QC program. Samples are planned for transport under chain-of-custody procedures to ALS Laboratories in South Africa, an ISO/IEC 17025-accredited laboratory independent of the Company. Gold analysis is planned by 30-gram fire assay with atomic absorption finish (Au-AA25), together with multi-element analysis by four-acid digestion and ICP-AES (ME-ICP61a). Samples returning more than 10 g/t gold are planned for gravimetric-finish re-assay (Au-GRA21), with additional checks as determined by the technical team and laboratory.

Structural measurements are being collected where reliable core orientation is available. Geological, sampling and survey records will be reconciled in the Company database, and assay results and associated QA/QC will be reviewed before public disclosure.

2026 Drilling Program and Next Steps
The approximately 3,000-meter HQ diamond program is focused on priority structural corridors at Vumba and is being executed by Mindea Exploration and Drilling Services (Pty) Ltd. The program is managed by Joe Van Wyk, Vice President, Exploration, and follows a decision-gated approach in which subsequent hole locations and orientations are refined as geological, structural, survey and assay information becomes available.

VUDD019 is now underway at Central–Makoba as a deeper northern test. The hole is designed to test continuity beneath and north of the deeper alteration/sulfidation packages observed in VUDD017 and to integrate the oblique structural information being developed from VUDD018. The approved geometry is 267° true / −69°, with a planned EOH of 425 meters. The Company will continue updating the three-dimensional model as VUDD018 logging is completed and VUDD019 drilling advances.

Cautionary Note Regarding Visual Observations
Visual identification of alteration, sulfides and quartz–carbonate veins is preliminary and is not a substitute for laboratory analysis. These observations do not establish gold grade, gold-bearing interval lengths, continuity or economic significance. No gold assays from VUDD018 are reported in this release. Analytical results will be disclosed following receipt, compilation, QA/QC review and verification.

Qualified Person
The scientific and technical information contained in this news release has been reviewed and approved by Rory Kutluoglu, P.Geo., a “Qualified Person” as defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects, who is independent of One Bullion.

The Company also announces today that it has amended its previously announced consulting agreement with SLD Capital Corp. (“SLD”) which formerly provided for the issuance to SLD of 83,333 common shares of the Company (“Common Shares”) per month over a six month term from June 1, 2026 to December 1, 2026. Pursuant to the terms of the revised agreement, the parties have agreed that SLD will instead be paid an aggregate fee of US$25,000 per month for the six month term, which shall be satisfied by the issuance of Common Shares at prevailing market prices on a monthly basis. In this regard, the Company will issue an aggregate of 281,268 Common Shares for the months of June, July and August, 2026 (or 93,756 Common Shares per month). All Common Shares issuable under the agreement will be subject to a statutory hold period of four months and one day following the date of issuance thereof. All future issuances of Common Shares remain subject to the approval of the TSX Venture Exchange.

About One Bullion
One Bullion Ltd. (TSXV: OBUL) is a Toronto-based gold exploration company focused on advancing high-quality gold assets in Botswana, one of Africa’s most stable and mining-friendly jurisdictions. Established in 2018, the Company controls approximately 8,004 km² of prospective land across three greenstone belt-hosted gold projects, including Vumba, Kraaipan, and Maitengwe. One Bullion’s strategy centers on disciplined, data-driven exploration combining modern geological methods with advanced targeting to identify and test high-priority gold targets while maintaining a commitment to environmental stewardship, community engagement, and long-term value creation for stakeholders.

Forward-Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and U.S. securities laws. Forward-looking information includes statements concerning the scope, sequencing and timing of the Company’s exploration program; completion of core logging and sampling; submission to the laboratory; anticipated analytical methods and assay turnaround; continued drilling of VUDD019 and subsequent holes; integration of geological, structural, survey and assay data into the three-dimensional model; and future targeting and drill-hole locations and orientations.

This information is based on management’s current expectations and assumptions, including the availability of funding, personnel, contractors and laboratory capacity; continued access to the projects and maintenance of required permits; the ability to complete sampling and drilling safely; and the suitability of the available geological data for ongoing interpretation. Forward-looking information is subject to risks and uncertainties, including changes in geological interpretations, assay results that do not support visual observations, variable core recovery and sample representativity, drilling or equipment problems, weather and access constraints, permitting delays, laboratory backlogs, additional QA/QC or verification requirements, funding availability and risks associated with operations in Botswana.

Actual results, work programs, costs and timelines may differ materially from those expressed or implied. There is no assurance that further drilling will identify economic mineralization or that the current geological interpretation will be confirmed. Readers should not place undue reliance on forward-looking information. Except as required by applicable law, the Company undertakes no obligation to update or revise it as a result of new information, future events or otherwise.

Cautionary Note Regarding United States Securities Laws
This news release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in a jurisdiction in which such offer, solicitation or sale would be unlawful. The Company’s securities have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons, as defined in Regulation S under the U.S. Securities Act, unless an exemption from registration is available.

Contact Information:
Adam Berk, Chief Executive Officer
OneBullion@KCSA.com

Investor Contact:
KCSA Strategic Communications
Jack Perkins or Valter Pinto
T: 212-896-1254
OneBullion@KCSA.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

MONTREAL, Oct. 01, 2026 (GLOBE NEWSWIRE) — Dynacor Group Inc. (TSX: DNG) (“Dynacor“ or the “Corporation“) is delighted to announce the appointment of mining executive Jonathan Hill as Chief Operating Officer (“COO”). In his role, Mr. Hill will guide Dynacor’s execution of its operational and strategic objectives, focusing on driving operational excellence, safety, talent success and technology enablement.

Mr. Hill’s appointment comes at a pivotal time when Dynacor is commissioning the first phase of its expansion strategy across South America and Africa.

“I am thrilled to welcome Jonathan to Dynacor’s executive team” said Daniel Misiano, President & CEO. “Jonathan brings the plant-building experience and operational discipline to lead our team into our next chapter of operational growth.  His multi-site leadership will build the strong systems, teams and processes needed to run them safely and profitably, and materially strengthens our ability to continue executing our expansion strategy.”

Mr. Hill brings more than 25 years of industrial and mining leadership experience, predominately across complex, multi-site operations in North America. Throughout his career, he has built, commissioned, optimised and managed operations, establishing a proven track record for operational discipline, technical rigour, cultural change and digital transformation.

Most recently, Mr. Hill served as General Manager, Integrated Operations and Operational Excellence at ArcelorMittal Mines Canada (AMMC) where he drove significant improvements in operational performance at Canada’s largest open-pit iron ore complex. As Mining Manager at AMMC, he provided proactive leadership that delivered operational targets and enhanced the safety culture at the Mont-Wright and Fire Lake mines. Mr. Hill also served as Manager, Technical Services at AMMC, where he strengthened technical governance and led optimisation of the two mines. Earlier roles include Operations Manager for Detour Gold  and Mine Manager for Nordgold in Burkina Faso.

Mr. Hill succeeds Daniel Misiano who was promoted to President & CEO in June 2026.

About Dynacor

Dynacor Group is an ore processing company dedicated to producing gold sourced from artisanal miners. Since its establishment in 1996, Dynacor has pioneered a responsible mineral supply chain with stringent traceability and audit standards for the fast-growing artisanal mining industry. By focusing on formalized miners, the Canadian company offers a win-win approach for governments and miners globally. Dynacor operates the Veta Dorada plant and owns a gold exploration property in Peru. The company is expanding to West Africa and within Latin America.

The premium paid by luxury jewellers for Dynacor’s PX Impact® gold goes to Fidamar Foundation, an NGO that mainly invests in health and education projects for artisanal mining communities in Peru. Visit www.dynacor.com for more information.

Forward-Looking Information

Certain statements in the preceding may constitute forward-looking statements, which involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Dynacor, or industry results, to be materially different from any future result, performance or achievement expressed or implied by such forward-looking statements. These statements reflect management’s current expectations regarding future events and operating performance as of the date of this news release.

Contact:

For more information, please contact:

Ruth Hanna
Director, Investor Relations
T: 514-393-9000 #236

E: investors@dynacor.com
Website: dynacor.com

Renmark Financial Communications Inc.
Bettina Filippone
T: (416) 644-2020 or (212) 812-7680
E: bfilippone@renmarkfinancial.com 
Website: renmarkfinancial.com

Appointment Enhances Support for Healthcare and Life Sciences Clients Navigating AI Risk, Regulation and Governance

WASHINGTON, Oct. 01, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Christina Morris as a Senior Managing Director in the Healthcare Risk Management & Advisory practice within the firm’s Forensic and Litigation Consulting segment.

Ms. Morris, who is based in Washington, D.C., has more than 25 years of experience helping global pharmaceutical and life sciences organizations modernize risk, regulatory compliance and quality operations to strengthen governance, controls and operational resilience through technology-enabled transformation initiatives. Her experience includes redesigning business processes and operating models through the strategic use of artificial intelligence, automation, process orchestration and related technologies.

In her role at FTI Consulting, Ms. Morris will work with clients to assess and modernize complex business processes and operating models through the strategic application of technology. Her focus will be on applying automation, data, AI and business process management to strengthen compliance, reduce operational risk, improve audit readiness, and create more efficient and resilient operating models.

“Healthcare organizations are evaluating how emerging technologies can improve performance while they continue to manage regulatory requirements, cost pressures and complex technology environments,” said Wayne T. Gibson, Leader of the Healthcare Risk Management & Advisory practice at FTI Consulting. “Christina brings experience connecting business strategy, technology and execution, which will help clients determine where AI and automation can create value and how those opportunities can be implemented responsibly at scale.”

Prior to joining FTI Consulting, Ms. Morris was a Managing Director at a Big Four firm, where she led technology-driven business transformation initiatives focusing on AI, GenAI, hyperautomation and intelligent platforms. She has also held senior positions at Hoverstate, FrontierBPM and EY and has spent more than 10 years in the healthcare and life sciences industry.

Commenting on her appointment, Ms. Morris said, “Organizations need a clear view of where technology can create economic and operational value, a practical plan for redesigning the underlying work and the ability to carry that transformation through execution, while reducing risk. I look forward to working with my colleagues across FTI Consulting to help clients build more productive, resilient and adaptable operating models.”

About FTI Consulting
FTI Consulting, Inc. is a leading global expert firm for organizations facing crisis and transformation, with more than 8,100 employees located in 32 countries and territories as of June 30, 2026. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalized and independently managed. The Company generated $3.8 billion in revenues during fiscal year 2025. More information can be found at www.fticonsulting.com.

FTI Consulting, Inc.
555 12th Street NW
Washington, DC 20004
+1.202.312.9100

Investor Contact:
Mollie Hawkes
+1.617.747.1791
mollie.hawkes@fticonsulting.com

Media Contact:
Nick Emmons
+1.617.510.1676
nick.emmons@fticonsulting.com

  • Oral presentation includes safety and efficacy data as of the July 2, 2026 data cutoff, highlighting clinically meaningful improvements in disease activity and symptoms at six months in 11 patients with longstanding, highly active Sjögren disease
  • Mean stimulated salivary flow increased from 0.4 to 1.1 mL/min among eight patients with baseline hyposalivation and available six-month data
  • Updated safety data across 73 Phase 2a basket study patients support the potential for outpatient administration, with no cytokine release syndrome, ICANS or treatment discontinuations due to adverse events

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today highlighted updated clinical, safety and translational data for AlloNK® (also known as AB-101) in combination with rituximab, presented by Guillermo J. Valenzuela, M.D., F.A.C.R., medical director of Integral Rheumatology & Immunology Specialists, in an oral session at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026) in Paris.

The presentation featured data from the first 11 patients with Sjögren disease (SjD) in Artiva’s ongoing company-sponsored Phase 2a basket trial who had at least six months of follow-up as of July 2, 2026. The study is single-arm and evaluates AlloNK plus rituximab following low-dose cyclophosphamide and fludarabine conditioning, with treatment administered intravenously in an outpatient setting.

“These updated Sjögren disease data build on the initial findings we presented at EULAR and show improvements across systemic disease activity, patient-reported symptoms and salivary function,” said Fred Aslan, M.D., chief executive officer of Artiva. “We believe these results support continued evaluation of AlloNK plus rituximab as an outpatient-administered deep B-cell depleting regimen for patients with B-cell-driven autoimmune diseases. We look forward to following these patients to assess the durability of their responses.”

Updated Sjögren disease data show improvement across clinical and functional measures

The 11 patients with SjD had longstanding, highly active disease despite prior standard therapies. All were women, and the mean disease duration was 12.2 years. At six months, mean ClinESSDAI, a measure of systemic disease activity, improved by 6.9 points from a baseline mean of 14.6. Mean ESSPRI, a patient-reported measure of dryness, fatigue and pain, improved by 3.5 points from a baseline mean of 8.0. Both mean changes exceeded the thresholds for minimal clinically important improvement shown in the presentation.

On the individual ESSPRI domains, 82% of patients had at least a one-point improvement in dryness, 55% in fatigue and 73% in pain at Week 24. Mean FACIT-Fatigue score increased by 13.0 points from a baseline mean of 18.1, indicating improvement, while mean patient global assessment improved by 3.5 points from a baseline mean of 7.21.

Among eight patients with baseline hyposalivation and six-month stimulated salivary-flow measurements available at the July 2, 2026 data cutoff, mean flow increased from 0.4 to 1.1 mL/min, exceeding the threshold for normal salivation of greater than 1.0 mL/min shown in the presentation.

Updated safety and translational data support outpatient treatment approach

Preliminary safety data as of July 2, 2026 included 73 patients in the Phase 2a basket study across SjD, rheumatoid arthritis, systemic sclerosis and inflammatory myositis, an expanded population from the 55 patients in the EULAR safety analysis. No cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), graft-versus-host disease or hypogammaglobulinemia was observed, and no patients discontinued treatment due to adverse events. Eight patients (11%) experienced serious adverse events, including two with serious infections reported as unrelated to AlloNK. The most common treatment-emergent adverse events were nausea (40%), headache (27%) and lymphopenia (25%). Two of 73 patients were hospitalized for treatment-emergent adverse events during the first 28 days; neither hospitalization was related to AlloNK.

The presentation also revisited translational findings previously reported at EULAR. Across several autoimmune studies, uniform B-cell depletion was observed by Day 13 in 51 patients, and B-cell reconstitution in 13 patients showed an increased proportion of naïve/transitional B cells. These findings are drawn from multiple autoimmune diseases and studies, beyond the 11-patient SjD cohort.

About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases. Artiva is initiating a Phase 3 registrational trial of its lead program, AlloNK® (also known as AB-101), for refractory rheumatoid arthritis (RA) during the second half of 2026. AlloNK is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved natural killer (NK) cell therapy candidate designed to enhance antibody-dependent cellular cytotoxicity in combination with a range of therapeutic antibodies. Initial clinical data evaluating AlloNK in combination with anti-CD20 antibodies have demonstrated encouraging activity across multiple B-cell-driven autoimmune diseases and a tolerability profile supportive of outpatient administration. Artiva is developing AlloNK plus rituximab as a scalable, outpatient-administered, deep B-cell depletion treatment regimen for use in community rheumatology settings. In addition to refractory RA, AlloNK is being evaluated in Sjögren disease, systemic sclerosis and myositis.

Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements may include, without limitation, statements regarding: the potential benefits, accessibility, practicality, effectiveness, safety and tolerability of AlloNK, including based on interim pooled data across clinical trials, and the potential for administration in an outpatient community setting; the registrational Phase 3 trial for AlloNK, including trial design, expectations for response rates, and timing of initiation, future updates on site activation and enrollment, and topline data readout; and Artiva’s ability to generate sufficient data to support a BLA submission; clinical data expected to be presented from patients with refractory RA, SjD and SSc, and the timing of such data disclosures; the number of patients with data from the basket study who would be expected to meet the key eligibility criteria for the planned Phase 3 trial; Artiva’s ability to realize the potential benefits associated with FDA RMAT designation for AlloNK; Artiva’s beliefs regarding its competitive position, including its belief that AlloNK may be the first deep B-cell depleting therapy of any modality to reach patients with, and be approved and commercialized in, refractory RA; and Artiva’s future results of operations and financial position, including cash runway. These forward-looking statements are based on the beliefs of the management of Artiva as well as assumptions made by and information currently available to Artiva. Such statements reflect the current views of Artiva with respect to future events and are subject to known and unknown risks and uncertainties, including, without limitation, risks and delays relating to initiation of the Phase 3 registrational trial, activation of clinical trial sites, patient enrollment and the availability and timing of disclosure of data; risks that future clinical trial results may not be consistent with interim, initial, preliminary, or topline results or results from prior preclinical studies or clinical trials, or with Artiva’s expectations; the risk that the number of patients, or the duration of follow-up for such patients, available for presentation differs from current expectations; the risk that differences exist between trial designs, patient characteristics and other factors for the Phase 3 trial, Artiva-sponsored Phase 2a basket trial and investigator-initiated basket trial, and caution should be exercised in drawing any conclusions from such data across separate trials as such pooling and comparative data is inherently limited and such data may not be directly comparable; the risk that other deep B-cell depleting therapies may advance more rapidly than Artiva currently anticipates, that Artiva’s assessment of publicly disclosed competitor development timelines may be incomplete or inaccurate, and that Artiva may not achieve or be the first to achieve regulatory approval or commercialization of a therapy in this category; the risk that Artiva’s registrational strategy is based in part on recent interactions with the FDA and later feedback from the FDA may be inconsistent with past interactions; Artiva’s ability to obtain adequate financing to fund its planned clinical trials and other expenses; risks inherent in developing product candidates; and risks related to the legal and regulatory framework for the industry. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause Artiva’s actual results to differ from current expectations are discussed in Artiva’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in Artiva’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, Artiva undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investors & Media
Noopur Batsha Liffick, MPH
NBL LifeSci Advisory LLC
ir@artivabio.com

Source: Artiva Biotherapeutics, Inc.

Meetings with Potential Partners and Investors Planned for Streamex Corp. and GLDY

WINTER PARK, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) — Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a technology company building the future of the commodity markets through tokenization, today announced that Henry McPhie, Co-Founder and Chief Executive Officer, will travel to Asia in October to attend multiple events in Singapore and Hong Kong. During the tour, Mr. McPhie will meet with potential partners and investors for Streamex and for GLDY, the Company’s gold-backed yield-bearing tokenized security.

The Asia tour reflects Streamex’s continued focus on building relationships with institutional investors, strategic partners and market participants across one of the world’s most active regions for digital assets and commodities trading. At the World Family Office Forum | Asia in Hong Kong, Mr. McPhie will participate on a panel and in 1:1 investor meetings to discuss Streamex, the Company’s roadmap and the growing opportunity for GLDY.

Henry McPhie, Co-Founder and Chief Executive Officer of Streamex, stated:

“Asian investors have been among the most forward-looking participants in digital assets and real-world asset tokenization, and their influence on how these markets develop continues to grow. We look forward to meeting with potential investors and partners across Singapore and Hong Kong to share our vision for bringing commodities on-chain.”

Singapore Events

Digital Asset Summit Asia 2026, October 7, 2026, Marina Bay Sands, Singapore. Mr. McPhie will attend Blockworks’ institutional digital asset conference, meeting with institutions and prospective partners.

Token2049 in Singapore, October 7–8, 2026. Mr. McPhie will attend Token2049, a leading digital asset industry gathering in Asia, meeting with prospective partners and investors.

Hong Kong Events

World Family Office Forum | Asia, October 15–16, 2026, The Ritz-Carlton, Hong Kong. Mr. McPhie will speak on the panel “Digital Assets & Blockchain: The Next Chapter of Innovation” on October 15 from 4:00 to 4:40 p.m. HKT. The panel will be moderated by Gabriel Karageorgiou of XBTO and includes Zann Kwan of Revo Digital Family Office and Leo Chiu of Click Ventures. The seventh edition of this forum convenes Asia’s leading business families, single family offices and their trusted advisors, and Mr. McPhie expects to meet with family offices and prospective investors for Streamex and GLDY.

How to Schedule a Meeting

Attendance at the forum is by invitation only. Qualified family offices and other interested parties may request an invitation at asia.worldfamilyofficeforum.com or contact the organizer, Connect Group, at info@connectgroup.global.

To arrange a meeting with the Streamex team while Mr. McPhie is in Singapore or Hong Kong, contact Streamex Investor Relations at IR@streamex.com.

About Streamex Corp.

Streamex Corp. (NASDAQ: STEX) is a technology and infrastructure company focused on the tokenization and digitalization of commodity real-world assets. Streamex delivers institutional-grade solutions that bridge traditional finance and blockchain-enabled markets through secure, regulated and yield-bearing financial instruments.

For more information, visit www.streamex.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Streamex’s business strategy, investor relations initiatives, Mr. McPhie’s planned participation in events and anticipated meetings with potential investors and partners in Asia and any resulting partnerships or investments, the market opportunity for GLDY, the development and scalability of its tokenization platform, and expectations for the tokenization of real-world assets. Such statements are often identified by words such as “will,” “expects,” “plans,” “anticipates,” “intends” and similar expressions. They are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including that planned events or meetings may be changed, rescheduled or canceled, that meetings may not result in any partnership, investment or other transaction, and risks related to market conditions, regulatory developments affecting tokenized securities and digital assets, and the Company’s ability to develop and scale its platform and products. Forward-looking statements speak only as of the date of this press release. Except as required by law, Streamex undertakes no obligation to update any forward-looking statement. Additional information regarding these and other risks is contained in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in its other filings with the Securities and Exchange Commission.

Contacts
Streamex Press & Investor Relations
 
Laura Kiernan
Head of Investor Relations
IR@streamex.com | laura@streamex.com
Henry McPhie
Chief Executive Officer, Streamex Corp.
www.streamex.com | X.com/streamex


MCI D45 CRT

WINNIPEG, Manitoba, Oct. 01, 2026 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI), a leading manufacturer of buses and motorcoaches and a provider of comprehensive aftermarket parts and service solutions, subsidiary Motor Coach Industries (MCI), has expanded its order with Metrolinx for 47 additional 45-foot D45 CRT diesel commuter coaches.

The expanded order comes through two agreements, one for 33 coaches and another for 14 coaches, expanding the 97-coach order announced in early July 2025 to a total of 144 coaches. With Metrolinx’s initial purchase of 80 coaches announced in the first quarter of 2025, the additions bring Metrolinx’s total commitment to 224 MCI coaches. The latest order will replace aging MCI coaches in the agency’s fleet.

“These additional orders are a strong testament to our partnership with Metrolinx and the confidence they place in MCI,” said Rob Marion, President, MCI. “The D45 CRT is purpose-built for demanding commuter applications, and we’re pleased to provide Metrolinx with coaches that deliver the safety, dependability, and passenger experience their customers expect.”

“Additional MCI coaches will increase our capacity to deliver safe and reliable bus service and reflect our ongoing commitment to connect the people and communities we serve,” said Rodney Jones, Vice President, Fleet & Electrification, Metrolinx. “We are excited to see the positive impact this will have on our bus operations.”

Metrolinx is an agency of the Government of Ontario responsible for coordinating and integrating transportation in the Greater Toronto and Hamilton Area (GTHA). The agency operates GO Transit, UP Express, and PRESTO and is advancing significant transportation investments designed to connect communities and support the region’s continued growth. GO Transit provides regional train and bus service across the GTHA and beyond.

MCI’s D45 CRT commuter coach is specialized for high-capacity commuter and regional transportation. The additional coaches will support Metrolinx as it continues to provide efficient regional transit and respond to transportation needs across the Greater Toronto and Hamilton Area.

About NFI

NFI is a leading global bus and motorcoach manufacturer and a provider of aftermarket parts and service solutions. With more than 9,000 team members across ten countries and operations spanning over 40 facilities, NFI delivers a comprehensive portfolio of bus and coach platforms.

Through its brands New Flyer® (heavy-duty transit buses), MCI® (motorcoaches), Alexander Dennis Limited (single- and double-deck buses), ARBOC® (low-floor cutaway and medium-duty buses), and NFI Parts™, NFI supports a diverse and extensive portfolio, serving public transit, commuter, and coach markets. In total, NFI supports an installed base of more than 100,000 buses and coaches worldwide. NFI offers a broad range of propulsion systems, including zero-emission electric (referring to propulsion systems that do not utilize internal combustion engines, such as trolley, battery, and fuel cell), natural gas, electric hybrid, and advanced diesel technologies, providing agencies with multiple fleet technology options. NFI’s common shares trade on the Toronto Stock Exchange (TSX: NFI) and its convertible unsecured debentures trade under the symbol NFI.DB. News and information is available at www.nfigroup.com, www.newflyer.com, www.mcicoach.com, nfi.parts, www.alexander-dennis.com, arbocsv.com, and carfaircomposites.com.

About MCI

MCI is North America’s leading manufacturer of public and private market motorcoaches. Products include the luxury J Series (an industry best-seller for more than two decades) and the workhorse D Series. MCI also provides maintenance, repair, 24-hour roadside assistance, parts, and technician training through the industry’s only Automotive Service Excellence (ASE) accredited and award-winning MCI Academy.

Forward-Looking Statements

This press release may contain forward-looking statements relating to expected future events and financial and operating results of NFI that involve risks and uncertainties. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, investors cannot be assured that actual results will be consistent with these forward-looking statements, and the differences may be material. Actual results may differ materially from management expectations as projected in such forward-looking statements for a variety of reasons, including market and general economic conditions (including as a result of tariffs and other trade measures) and economic conditions of and funding availability for customers to purchase buses and to purchase parts or services (including as a result of recent U.S. policy developments); customers may not exercise options to purchase additional buses; the ability of customers to suspend or terminate contracts for convenience; production may be delayed or production rates may be decreased as a result of ongoing and future supply chain disruptions and shortages of parts and components, shipping and freight delays, and disruption to and shortage of labor supply; and the other risks and uncertainties discussed in the materials filed with the Canadian securities regulatory authorities and available on SEDAR at www.sedarplus.ca.  

Due to the potential impact of these factors, NFI disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law. 

For media inquiries, please contact: 
Melissa Schnee 
P: 385.910.6861 
Melissa_Schnee@newflyer.com 

For investor inquiries, please contact: 
Stephen King 
P: 204.792.1300 
Stephen.King@nfigroup.com 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0269dc1c-6381-40f8-8f24-5c02de3dceb7

Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers

WVE-006 (RNA editing) has potential to offer the AATD community a new standard-of-care treatment to protect the liver and lung with a safe and convenient therapy

CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) — Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced alignment with the U.S. Food and Drug Administration (FDA) on key aspects of its planned registrational pathway for WVE-006, an investigational GalNAc-RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency (AATD). Following the company’s FDA meeting, planning is underway for a two-year registrational trial to support potential full approval, with a one-year interim analysis to support potential accelerated approval based on AATD biomarkers. Additionally, the FDA supports the use of Wave’s current LC-MS assay to measure M-AAT (wild-type) and Z-AAT (mutant) protein for the WVE-006 registrational program.

“A registrational trial design that offers an efficient path to full approval, without the need for a separate confirmatory trial, is advantageous as we work to bring WVE-006 to the ~200,000 individuals living with Pi*ZZ AATD in the U.S. and Europe. Our discussions with key opinion leaders underscore the high unmet need and burden of the current standard of care, IV augmentation therapy, which may leave patients with depleted AAT levels during lung exacerbations, and does not address the risk of liver disease. WVE-006 avoids the irreversible bystander edits, indels and other off-target edits associated with DNA base editing. With the potential to address both lung and liver AATD with infrequent subcutaneous dosing and a favorable safety profile, we believe WVE-006 could meaningfully improve patients’ quality of life and offer a comprehensive treatment approach,” said Christopher Wright, MD, PhD, Chief Medical Officer at Wave Life Sciences.

WVE-006 is being evaluated in the ongoing Phase 1b/2a RestorAATion-2 open-label clinical trial in individuals with AATD who have the homozygous Pi*ZZ mutation, and Wave is on track to share data from the 600 mg (monthly) multidose cohort in the fourth quarter of 2026. WVE-006 continues to be generally safe and well tolerated with no liver toxicities.

About WVE-006
WVE-006 is a GalNAc-conjugated, subcutaneously delivered, A-to-I RNA editing oligonucleotide (AIMer) that was developed with Wave’s best-in-class oligonucleotide chemistry platform. By correcting the single RNA base mutation associated with the Pi*ZZ genotype, WVE-006 is designed to deliver a comprehensive treatment approach for AATD by producing healthy, wild-type M-AAT, decreasing unhealthy, mutant Z-AAT aggregates in liver, and dynamically increasing AAT, a protein responsible for protecting lungs against ongoing damage.

About Alpha-1 Antitrypsin Deficiency (AATD)
AATD can manifest as both lung and liver disease. It is a rare, inherited genetic disorder caused by a G-to-A point mutation in the SERPINA1 gene, referred to as the Z allele. Approximately 200,000 people in the U.S. and Europe are homozygous for the Z allele. In healthy individuals, wild-type, M-AAT protects the lung from proteolytic and inflammatory damage, particularly during exacerbations. In AATD, instead of wild-type, functional M-AAT traveling through the bloodstream to the lungs, mutant Z-AAT protein tends to get trapped in the liver and causes a lack of functional AAT in the lungs. Further, Pi*ZZ individuals have a reduced capacity to produce incremental AAT protein during an acute phase response. Together, these effects can lead to progressive lung disease, including chronic obstructive pulmonary disease (COPD) and early-onset emphysema, as well as liver disease, including fibrosis, cirrhosis, and hepatocellular carcinoma.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, our plans for an efficient registrational trial; our understanding of the anticipated therapeutic benefits of WVE-006 as a therapy for AATD and the potential to address both lung and liver manifestations of the disease; WVE-006’s advantages in avoiding irreversible bystander edits, indels and other off-target edits associated with DNA base editing; our estimates of the AATD patient population that may benefit from WVE-006; our understanding of the dose levels and dosing frequency for WVE-006; our plans and estimated timing to share additional data from the RestorAATion-2 trial; our understanding of the safety profile of WVE-006. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release and actual results may differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com

WARMINSTER, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the final results of its tender offer (the “Offer”) to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”). The Offer proceeded by way of a modified Dutch auction, which had a tender price range from US$5.00 per Share to US$5.75 per Share, and included the option for shareholders to participate via a proportionate tender. The Offer expired at 5:00 p.m. (New York City time) on September 29, 2026. All amounts are in U.S. dollars.

In accordance with the terms and conditions of the Offer and based on the final calculation of TSX Trust Company, as depositary for the Offer (the “Depositary”), Arbutus has taken up and accepted for purchase a total of 46,000,000 Shares at a price of US$5.00 per Share under the Offer (the “Purchase Price”), representing an aggregate purchase price of US$230 million, excluding fees and expenses relating to the Offer, and approximately 23 percent of the total number of Arbutus’s issued and outstanding Shares as of the close of business on September 29, 2026. Immediately following completion of the Offer, Arbutus anticipates that approximately 153,275,907 Shares will be issued and outstanding.

Based on the final calculation of the Depositary, 65,709,919 Shares were validly tendered and not properly withdrawn pursuant to auction tenders at or below the Purchase Price and pursuant to purchase price tenders, which includes shares that were tendered through notice of guaranteed delivery at the final Purchase Price of US$5.00 per share or as purchase price tenders. Since the Offer was oversubscribed, shareholders who made auction tenders at or below the Purchase Price and shareholders who made, or were deemed to have made, purchase price tenders had approximately 55.6% of their tendered Shares taken up by Arbutus (other than “odd lot” tenders, which were not subject to proration). Shareholders who made auction tenders at a price in excess of the Purchase Price did not have any of those Shares purchased by Arbutus. 9,307,231 Shares were taken up and accepted for purchase pursuant to proportionate tenders, which were purchased in a separate pool and were not subject to proration.

Roivant Sciences Ltd., the beneficial owner of 38,847,462 Shares, approximately 19.5% of Arbutus’s issued and outstanding Shares as of September 29, 2026, made a proportionate tender under the Offer and will maintain its proportionate Share ownership at approximately 19.5% following completion of the Offer.

Arbutus has accepted for purchase 46,000,000 Shares validly tendered and not validly withdrawn and is making payment for the Shares by delivering the aggregate purchase price to the Depositary. Payment and settlement with shareholders will be effected by the Depositary on or about October 5, 2026, all in accordance with the Offer and applicable law. Any Shares not purchased, including Shares not purchased as a result of proration, Shares tendered pursuant to auction tenders at prices higher than the Purchase Price and invalidly tendered Shares, will be returned to shareholders as soon as practicable by the Depositary.

To assist shareholders in determining the tax consequences of the Offer, Arbutus does not expect that a deemed dividend will arise on a disposition of Shares pursuant to the Offer for purposes of the Income Tax Act (Canada). Shareholders should refer to the offer to purchase and issuer bid circular dated August 24, 2026 and consult with their own tax advisors with respect to the income tax consequences of the disposition of their Shares under the Offer.

The full details of the Offer are described in the offer to purchase and issuer bid circular dated August 24, 2026, as well as the related letter of transmittal and notice of guaranteed delivery, copies of which were filed and are available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.

This news release is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell Shares.

About Arbutus  

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is currently developing imdusiran (AB-729) and an oral PD-L1 inhibitor (AB-101) for the treatment of chronic hepatitis B infection. The Company is also consulting closely with and supporting its exclusive licensee, Genevant Sciences, to protect and defend its intellectual property, which is the subject of on-going lawsuits against Pfizer/BioNTech for use of Arbutus’ patented LNP technology in their COVID-19 vaccines. For more information, visit www.arbutusbio.com.

Forward-Looking Statements and Information

This press release contains “forward-looking statements,” including statements regarding completion of the Offer; the number of Shares issued and outstanding following completion of the Offer, the timing of payment and settlement with shareholders by the Depositary; the return of Shares not purchased as a result of proration or Shares tendered pursuant to auction tenders at prices higher than the Purchase Price or invalidly tendered Shares; the Company’s expectation that a deemed dividend will not arise on a disposition of Shares pursuant to the Offer for purposes of the Income Tax Act (Canada), and other terms and conditions of the Offer, which involve known and unknown risks, uncertainties and other factors that may cause actual results and other events to be materially different from those expressed or implied by such forward-looking statements.

The forward-looking statements contained in this press release are subject to a number of material factors that could cause actual results to differ materially, including, developments or changes in general economic or market conditions, developments or changes in the securities markets, developments or changes in our business, financial condition or cash flows, as well as other risks detailed in our Annual Report on Form 10-K for the most recent fiscal year as filed with the SEC.

A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus’ Annual Report on Form 10-K for the most recent fiscal year as filed with the SEC, Arbutus’ Quarterly Reports on Form 10-Q and Arbutus’ continuous and periodic disclosure filings, which are available at www.sec.gov and at www.sedarplus.ca. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus undertakes no obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

CONTACT: Arbutus Biopharma Corporation ir@arbutusbio.com

1,413.5 metres completed across three (3) drill pads testing approximately 300 metres strike-length of the Alps-Alturas shear zone, with locally massive stibnite encountered in drill hole ALTW-26-006

VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) — Maxus Mining Inc. (“Maxus” or the “Company”) (CSE: MAXM | OTCQB: MXMGF | FRA: R7V) is pleased to announce the completion of its inaugural diamond drill program (the “Program”) at the flagship Alturas West Antimony Project (“Alturas West” or the “Project”), located in the Slocan Mining Division of southeastern British Columbia.

The 2026 drill Program represents the first known surface drilling program completed on the Alturas West claim block. The Company completed eleven (11) diamond drill holes totaling 1,413.5 metres from three (3) drill pads. The drill Program tested targets across approximately 300 metres of strike length along the Alps-Alturas shear zone, targeting the structural corridor associated with the historic Alps-Alturas antimony mine and previously identified antimony mineralization at surface.

Multiple intervals of visible disseminated and vein-hosted stibnite and other sulphide/sulphosalt mineralization have been observed in all 2026 drill holes, apart from holes ALTW-26-008 and ALTW-26-010. Of particular note, drill hole ALTW-26-006 encountered a locally massive stibnite vein from 46.15 to 46.55 metres, representing the most visually significant occurrence of mineralization observed during the Program. Table 1 outlines the drill hole locations, orientations, and depths from the Program. Geochemical assays are pending, and visual confirmation of antimony-bearing minerals is not a direct indication of antimony grades and should not be considered a substitute for analytical results.

Figure 1

Figure 1: Locally massive stibnite vein observed in drill hole ALTW-26-006, at 46.15 m to 46.55 m. Mineral identification is based on visual observation and assay results are pending.

Scott Walters, Chief Executive Officer of Maxus, commented: “Completing the first-ever drill Program at Alturas West represents an important milestone for Maxus. We are encouraged to have confirmed visible antimony-bearing minerals in nine of eleven holes, including locally massive stibnite in ALTW-26-006, while also intersecting broad zones of shearing, alteration and veining across all three drill pads. This Program has provided our first subsurface view of approximately 300 metres of strike-length along the Alps-Alturas shear zone and an important new geological dataset that we can integrate with our geophysical and surface exploration work. We look forward to receiving the analytical results as they become available through the fall.”

2026 Alturas West Drill Program Highlights

  • 1,413.5 metres completed in eleven (11) diamond drill holes from three (3) drill pads (Please see Table 1);
  • Visible antimony-bearing mineralization observed in nine (9) of eleven (11) holes, including visible stibnite and other sulphide/sulphosalt mineralization (Please see Table 1);
  • Local massive stibnite encountered in ALTW-26-006, representing the most visually significant antimony mineralization observed during the Program (Please see Figure 1);
  • Broad zones of shearing and hydrothermal alteration intersected across all three (3) drill pads, accompanied by quartz-carbonate veining and locally extensive listwanite alteration;
  • Approximately 300 metres of strike length of the Alps-Alturas shear zone tested, providing the first subsurface geological information across this portion of the mineralized structural corridor (Please see Figure 2); and
  • All drill core submitted for laboratory analysis, with results expected to be received progressively through the fall 2026 season.

Table 1: Alturas West Drill Hole Collar Information

Hole ID Northing (m) Easting (m) Elevation (m) Length (m) Collar Azimuth (°) Collar Dip (°)
UTM NAD83 Zone 11N
ALTW-26-001 5551974 481312 2328 174.0 180.0 -55.0
ALTW-26-002 5551976 481312 2329 156.5 179.0 -70.0
ALTW-26-003 5551977 481312 2329 95.0 142.5 -89.1
ALTW-26-004 5551976 481311 2329 83.0 225.4 -70.1
ALTW-26-005 5551873 481021 2391 173.0 310.0 -45.1
ALTW-26-006 5551873 481021 2391 95.0 309.9 -70.0
ALTW-26-007 5551870 481024 2389 167.0 300.0 -45.0
ALTW-26-008 5551873 481021 2391 65.0 300.0 -70.0
ALTW-26-009 5551874 481021 2391 161.0 315.0 -47.0
ALTW-26-010 5551871 481024 2389 20.0 180.0 -70.0
ALTW-26-011 5552007 481222 2401 224.0 185.0 -70.0
 

Preliminary Results – Geology and Mineralization

Drilling across the three (3) drill pads intersected structurally complex and variably altered sequences of volcanic and intrusive rocks crosscut by multiple zones of shearing and quartz-carbonate veining. Broad zones of hydrothermal alteration were encountered throughout the drilled area, including sericite-fuchsite, silica-sericite, carbonate and chlorite alteration, together with locally extensive listwanite development.

Intervals of disseminated and vein-hosted antimony-bearing minerals were observed in all drill holes except ALTW-26-008 and ALTW-26-010, principally in association with altered and sheared intervals and quartz-carbonate veining. Mineralization observed in drill core includes visible stibnite and other sulphide/sulphosalt minerals. The most visually significant occurrence encountered during the Program was a locally massive stibnite vein in drill hole ALTW-26-006 (Please see Figure 1).

Drill core observations provide the Company with its first subsurface geological information across the mineralized Alps-Alturas shear corridor. The occurrence of repeated zones of shearing, alteration, and veining within individual drill holes suggests that the Alps-Alturas corridor is expressed as a broader, internally complex structural and hydrothermal system rather than solely as a single discrete structure.

The widespread occurrence of shearing, hydrothermal alteration, veining, and disseminated antimony-bearing minerals across all three (3) drill pads confirms a widespread mineralizing system along the Alps-Alturas shear corridor. These observations will be integrated with surface geology, structural measurements, and geophysical modelling to further refine the Company’s geological interpretation of the mineralized system.

All mineral identifications reported herein are based on visual observations of drill core and have not yet been confirmed by laboratory analysis. Visual observations should not be considered a substitute for analytical results.

First Drill Test of the Alps-Alturas Shear Zone

The 2026 Program was designed to provide the first systematic drill test of the Alps-Alturas shear zone associated with the historic Alps-Alturas antimony mine. Prior to drilling, the Company integrated historical exploration information, surface mapping and prospecting, structural measurements, and newly acquired VTEM geophysical data to develop and refine subsurface targets along the mineralized structural corridor.

Recent Maxwell plate modelling of the Company’s 2026 VTEM data identified multiple modelled conductive bodies extending over more than 900 metres of strike-length along the mapped Alps-Alturas shear corridor.2 The modelling identified several conductive features beneath and adjacent to the historic workings. Several modelled bodies dip approximately 45 degrees north, broadly consistent with the Company’s geological interpretation of the shear zone.

The completed drill Program tested approximately 300 metres of strike-length along this broader structural corridor from three (3) drill pads. Geological and structural information collected from the drill core will now be integrated with surface mapping, historical workings and the Company’s geophysical interpretation to further refine the three-dimensional geological and structural model of the Alturas West mineralized system.

The recent geophysical interpretation also suggests that the structural corridor may be more complex than a single continuous planar feature, with variations in modelled conductor geometry potentially reflecting structural offsets, cross-faulting, or changes in orientation.

Figure 2

Figure 2: Plan view of the Alturas West target area showing the three (3) 2026 drill pads and completed drill holes testing approximately 300 metres of strike along the Alps-Alturas shear zone.

Sampling, Analysis and QA/QC

Drill core from the 2026 Alturas West Program was logged, photographed and sampled under the supervision of Company geological personnel. Core samples were selected based on geological contacts, alteration, veining, and observed mineralization, with appropriate quality assurance/quality control (“QA/QC”) samples inserted into the sample stream.

Core samples from the completed drill program have now been submitted for laboratory analysis. Samples from ten (10) of the eleven (11) drill holes have been submitted to AGAT Laboratories in Calgary, with analytical results currently expected within approximately 8 to 12 weeks of submission.

Drill hole ALTW-26-007 was completed in support of the Company’s early-stage metallurgical and ore-sorting evaluation program. Samples from ALTW-26-007 have been submitted to ALS Geochemistry in North Vancouver for primary analytical work and will also support further early-stage ore-sorting studies.

Early-stage metallurgical testing and ore-sorting evaluation formed part of the Company’s original 2026 Alturas West exploration strategy, with the objective of evaluating processing characteristics and potential pre-concentration and waste-rejection opportunities early in the exploration process.

Analytical results from the drill Program are expected to be received progressively through the fall 2026 season.

Next Steps

With drilling now complete, Maxus will focus on integrating detailed geological, structural, and geophysical modelling and analytical results into the evolving geological model for Alturas West.

Pending receipt of assay results, the Company will evaluate the distribution, grade, and continuity of antimony and associated polymetallic mineralization encountered during the inaugural drill Program. Results from the early-stage metallurgical and ore-sorting work will also be incorporated into the Company’s ongoing evaluation of the Project.

The 2026 Program has provided the first subsurface geological test of the Alps-Alturas mineralized system and established a new geological dataset across approximately 300 metres of the broader structural corridor. These results will be integrated with the more than 900 metres of modelled conductive strike extent identified through recent geophysical modelling to assist in evaluating potential follow-up targets.

Community Engagement

Maxus recognizes that meaningful engagement with First Nations and local communities is an important component of responsible mineral exploration. The Company remains committed to maintaining transparent communication, minimizing environmental disturbance, and building respectful long-term relationships as exploration activities progress.

Qualified Person Statement

The scientific and technical information contained in this news release has been reviewed, verified, and approved by Morgan Verge, P.Geo., VP Exploration of the Company and a “qualified person” as defined in NI 43-101 – Standards of Disclosure for Mineral Projects. Ms. Verge has examined information regarding the historical exploration at the Project, which includes a review of the historical sampling, analytical, and procedures underlying the information and opinions contained herein.

Management cautions that historical results collected and reported by operators unrelated to Maxus have not been verified nor confirmed by its Qualified Person; however, the historical results create a scientific basis for ongoing work at the Project. Management further cautions that historical results, discoveries and published resource estimates on adjacent or nearby mineral properties, whether in stated current resource estimates or historical resource estimates, are not necessarily indicative of the results that may be achieved on the Project.

About Maxus Mining Inc.

Maxus Mining Inc. (CSE: MAXM | OTCQB: MXMGF | FRA: R7V) is a mineral exploration company focused on locating, acquiring, and, if warranted, advancing economic mineral properties in premier jurisdictions. The Company is actively progressing its diversified portfolio totaling approximately 16,490 hectares of prospective terrain across British Columbia, Canada.

The Portfolio includes 9,492 hectares across three antimony projects, anchored by the Flagship Alturas Antimony Project, where a recent discovery returned high-grade naturally occurring antimony up to 69.98% Sb. The Hurley Antimony Project, located adjacent to Endurance Gold Corp.’s Reliance Gold Project, where 2024 drilling reported 19.2% Sb and 2.16 g/t Au over 0.5 m‖, and the Quarry Antimony Project, which hosts historical polymetallic samples grading 0.89 g/t Au, 3.8% Cu, 0.34% Zn, 42.5% Pb, 0.65 g/t Ag, and 20% Sb‡.

Maxus’ portfolio further includes the 3,875-hectare Lotto Tungsten Project, where a selected 1980 grab sample from a scheelite-bearing quartz vein assayed 10.97% WO₃§, and the 3,123-hectare Penny Copper Project, which has over 100 years of recorded exploration. Recent work programs at Penny included rock sampling and geological mapping†, with 2017 sampling returning copper values of 1046 ppm Cu (TK17-149c), 1808 ppm Cu (TK17-28), and 2388 ppm Cu (TK17-12)†. The Project is strategically located near the historic Sullivan Mine at Kimberley, British Columbia, an area that continues to attract significant exploration activity.

Maxus Mining is committed to advancing its British Columbia projects through targeted exploration programs designed to unlock value across multiple critical mineral systems.

References

1 Alps-Alturas MINFILE – Link

2 Maxus Mining News Release – September 15, 2026 – ‘Maxus Mining Refines Alturas West Drill Targets with VTEM Interpretation and Maxwell Plate Modelling’ Link

 Equinox Resources – November 8, 2024, ‘Ultra High Grade Naturally Occurring Antimony at Alturas Project with Assays up to 69.98% Sb’ – Link

‖ ‘Endurance Summarizes Antimony Results From The Reliance Gold Project, BC – Best Intervals Include 19.2% Antimony And 2.16 ppm Au Over 0.5 m In 2024 Drilling’ – February 24, 2025 – Link

‡ Open File 1992-11, Map Number 10.

§ MILFILE No: 082FSW228 – Loto 3, 1980 Grab Sample Link

† NI 43-101 – Technical Report on the Penny Property British Columbia, NTS 82G/12 49° 55° North Latitude -115° 90° West Longitude, Derrick Strickland P.Geo., August 14, 2024.

On Behalf of the Board of Directors

Scott Walters
Chief Executive Officer, Director
+1 (778) 374-9699
info@maxusmining.com

Disclaimer for Forward-Looking Information

This news release includes certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” under applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target”, “plan”, “forecast”, “may”, “would”, “could”, “schedule” and similar words or expressions, identify forward-looking statements or information.

Forward-looking statements and forward-looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Maxus’, future growth potential for Maxus and its business, and future exploration plans are based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of copper, gold, tungsten, antimony and other metals; costs of exploration and development; the estimated costs of development of exploration projects; Maxus’ ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

This news release contains “forward-looking information” within the meaning of the Canadian securities laws. Statements, other than statements of historical fact, may constitute forward looking information and include, without limitation, statements with respect to the Project and its mineralization potential; the Company’s objectives, goals, or future plans with respect to the Project; further exploration work on the Project in the future; the expected benefits of completing the Program; and the commencement of drilling or exploration programs in the future. With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions regarding, among other things, the geological, metallurgical, engineering, financial and economic advice that the Company has received is reliable and are based upon practices and methodologies which are consistent with industry standards. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: fluctuations in commodity prices and currency exchange rates; uncertainties relating to interpretation of well results and the geology, continuity and grade of copper, gold, tungsten, antimony and other metal deposits; uncertainty of estimates of capital and operating costs, recovery rates, production estimates and estimated economic return; the need for cooperation of government agencies in the exploration and development of properties and the issuance of required permits; the need to obtain additional financing to develop properties and uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs or in construction projects and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; increased costs and restrictions on operations due to compliance with environmental and other requirements; increased costs affecting the metals industry and increased competition in the metals industry for properties, qualified personnel, and management. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

The Canadian Securities Exchange (CSE) does not accept responsibility for the adequacy or accuracy of this release.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/4bf43587-ec32-4329-8b77-fd5066914e73

https://www.globenewswire.com/NewsRoom/AttachmentNg/7fcae58a-6e90-4931-947b-774d5730b67b

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.